Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic TNBC
NCT07876557Phase 2Not yet recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of JS212 in triple-negative breast cancer (TNBC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
JS212
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07876557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876557.